This point has to be kept in mind because (i) the B1R is induced specifically in the diseased organ and thus potentially displays low side effects and (ii) it might become an alternative therapy in cases of poor tolerability due to the known adverse effects (chronic cough, hyperkalemia, angio-edema) of angiotensin converting enzyme inhibitors or to a lesser extent of AT1 receptor antagonist. The gene discussed is ACE; the disease is Hyperkalemia.